Skip to content

Memokath Prostatic Stent Study

Pilot investigation of the effect of the Memokath 028 Prostate® stent on quality of life in patients with urethral obstruction a comparison with long term catheter

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN33583715
Enrollment
60
Registered
2012-04-11
Start date
2011-11-15
Completion date
Unknown
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal surgery Surgery

Interventions

This pilot trial will recruit 60 men with retention of urine, and these will be randomised in a 1:1 ratio to either continue with the long term catheter that they already have fitted or to have a pros

Sponsors

Royal Devon and Exeter Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Men aged 50 years and older 2. Acute or chronic urinary retention initially treated with a urethral catheter 3. Considered to be medically unfit for, or to present a significant risk for TURP, such that the admitting urologist would consider a long term catheter to be the standard management. 4. Considered by the admitting urologist and trial team to be medically suitable to be managed with a long term prostatic stent

Exclusion criteria

Exclusion criteria: 1. Inability or unwillingness to sign informed consent form / any written questionnaire and participate in investigation due to physical or mental limitations 2. Meatal or urethral strictures that cannot be opened to 26 Fr 3. Urethral diverticuli 4. Any known condition requiring transurethral manipulations within 6 months after stent placement 5. Bladder stones, bladder or urethral carcinoma 6. Prior TURP or other surgical intervention for BPH within the last year 7. Presence of another urological prosthesis 8. Unresolved major symptomatic medical problem which would interfere with the investigation, including any and all disorders contraindicating insertion and/or removal procedure 9. Life expectancy < 1 year 10. Concurrent participation in another clinical trial during the period of this investigation

Design outcomes

Primary

MeasureTime frame
Health Related Quality of Life measured using: 1. SF-36 at baseline, 3 months and 6 months 2. ICIQ-MLUTS at baseline, 3 months and 6 months 3. ICIQ-LUTSqol at baseline, 3 months and 6 months

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026